130 related articles for article (PubMed ID: 11141350)
41. RAR-, not RXR, ligands inhibit cell activation and prevent apoptosis in B-lymphocytes.
Lømo J; Smeland EB; Ulven S; Natarajan V; Blomhoff R; Gandhi U; Dawson MI; Blomhoff HK
J Cell Physiol; 1998 Apr; 175(1):68-77. PubMed ID: 9491782
[TBL] [Abstract][Full Text] [Related]
42. The effects of RARalpha and RXRalpha proteins on growth, viability, and differentiation of v-myb-transformed monoblasts.
Vodicka P; Sevcíková S; Smardová J; Soucek K; Smarda J
Blood Cells Mol Dis; 2000 Aug; 26(4):395-406. PubMed ID: 11042040
[TBL] [Abstract][Full Text] [Related]
43. Novel retinoic acid receptor alpha agonists for treatment of kidney disease.
Zhong Y; Wu Y; Liu R; Li Z; Chen Y; Evans T; Chuang P; Das B; He JC
PLoS One; 2011; 6(11):e27945. PubMed ID: 22125642
[TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
Clarke E; Jarvis CI; Goncalves MB; Kalindjian SB; Adams DR; Brown JT; Shiers JJ; Taddei DMA; Ravier E; Barlow S; Miller I; Smith V; Borthwick AD; Corcoran JPT
Bioorg Med Chem; 2018 Feb; 26(4):798-814. PubMed ID: 29288071
[TBL] [Abstract][Full Text] [Related]
45. Two distinct actions of retinoid-receptor ligands.
Chen JY; Clifford J; Zusi C; Starrett J; Tortolani D; Ostrowski J; Reczek PR; Chambon P; Gronemeyer H
Nature; 1996 Aug; 382(6594):819-22. PubMed ID: 8752277
[TBL] [Abstract][Full Text] [Related]
46. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development.
Kim MJ; Deplewski D; Ciletti N; Michel S; Reichert U; Rosenfield RL
Mol Genet Metab; 2001 Nov; 74(3):362-9. PubMed ID: 11708867
[TBL] [Abstract][Full Text] [Related]
47. A molecular basis for retinoic acid-induced axial truncation.
Iulianella A; Beckett B; Petkovich M; Lohnes D
Dev Biol; 1999 Jan; 205(1):33-48. PubMed ID: 9882496
[TBL] [Abstract][Full Text] [Related]
48. Comparative teratogenic activities of two retinoids: effects on palate and limb development.
Kochhar DM; Penner JD; Tellone CI
Teratog Carcinog Mutagen; 1984; 4(4):377-87. PubMed ID: 6149630
[TBL] [Abstract][Full Text] [Related]
49. Multiple factors contribute to the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): binding affinities and disposition.
Pignatello MA; Kauffman FC; Levin AA
Toxicol Appl Pharmacol; 1997 Feb; 142(2):319-27. PubMed ID: 9070355
[TBL] [Abstract][Full Text] [Related]
50. A retinoic acid receptor alpha antagonist counteracts retinoid teratogenicity in vitro and reduced incidence and/or severity of malformations in vivo.
Eckhardt K; Schmitt G
Toxicol Lett; 1994 Feb; 70(3):299-308. PubMed ID: 8284797
[TBL] [Abstract][Full Text] [Related]
51. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers.
Vivat V; Zechel C; Wurtz JM; Bourguet W; Kagechika H; Umemiya H; Shudo K; Moras D; Gronemeyer H; Chambon P
EMBO J; 1997 Sep; 16(18):5697-709. PubMed ID: 9312028
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and pharmacological characterization of Disila-AM80 (Disila-tamibarotene) and Disila-AM580, silicon analogues of the RARalpha-selective retinoid agonists AM80 (Tamibarotene) and AM580.
Tacke R; Müller V; Büttner MW; Lippert WP; Bertermann R; Daiss JO; Khanwalkar H; Furst A; Gaudon C; Gronemeyer H
ChemMedChem; 2009 Nov; 4(11):1797-802. PubMed ID: 19790202
[No Abstract] [Full Text] [Related]
53. Role of the retinoic acid receptor-α in HIV-associated nephropathy.
Ratnam KK; Feng X; Chuang PY; Verma V; Lu TC; Wang J; Jin Y; Farias EF; Napoli JL; Chen N; Kaufman L; Takano T; D'Agati VD; Klotman PE; He JC
Kidney Int; 2011 Mar; 79(6):624-634. PubMed ID: 21150871
[TBL] [Abstract][Full Text] [Related]
54. Selective Retinoic Acid Receptor γ Agonists Promote Repair of Injured Skeletal Muscle in Mouse.
Di Rocco A; Uchibe K; Larmour C; Berger R; Liu M; Barton ER; Iwamoto M
Am J Pathol; 2015 Sep; 185(9):2495-504. PubMed ID: 26205250
[TBL] [Abstract][Full Text] [Related]
55. Effect of supplementation with folinic acid, vitamin B6, and vitamin B12 on valproic acid-induced teratogenesis in mice.
Elmazar MM; Thiel R; Nau H
Fundam Appl Toxicol; 1992 Apr; 18(3):389-94. PubMed ID: 1597263
[TBL] [Abstract][Full Text] [Related]
56. The role of metabolism and toxicokinetics in retinoid teratogenesis.
Tzimas G; Nau H
Curr Pharm Des; 2001 Jun; 7(9):803-31. PubMed ID: 11375780
[TBL] [Abstract][Full Text] [Related]
57. Comparative teratogenicity of three retinoids: the arotinoids Ro 13-7410, Ro 13-6298 and Ro 15-1570.
Kistler A; Galli B; Howard WB
Arch Toxicol; 1990; 64(1):43-8. PubMed ID: 2306193
[TBL] [Abstract][Full Text] [Related]
58. Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.
Thoreau E; Arlabosse JM; Bouix-Peter C; Chambon S; Chantalat L; Daver S; Dumais L; Duvert G; Feret A; Ouvry G; Pascau J; Raffin C; Rodeville N; Soulet C; Tabet S; Talano S; Portal T
Bioorg Med Chem Lett; 2018 Jun; 28(10):1736-1741. PubMed ID: 29706423
[TBL] [Abstract][Full Text] [Related]
59. Teratogenic profile of retinylidene methyl nitrone and retinol in Swiss-Webster mice.
Willhite CC; Balogh-Nair V
Teratog Carcinog Mutagen; 1985; 5(5):355-63. PubMed ID: 2867618
[TBL] [Abstract][Full Text] [Related]
60. [From cancer prevention to cancer treatment].
Shudo K
Yakugaku Zasshi; 2000 Oct; 120(10):987-95. PubMed ID: 11082709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
